Latest Research And Development News

Cleo Diagnostics (ASX:COV) posted a 48% jump in annual loss to $5.9 million amid key progress in its ovarian cancer diagnostic test, including completion of a pivotal US trial and preparations for FDA 510(k) submission.

Telix Pharmaceuticals returned to profit in H1 2026, driven by strong U.S. sales of Illuccix and Gozellix, a $40 million upfront from Regeneron collaboration, and expanded R&D investment.

Percheron Therapeutics reduced its FY2026 loss to $4.79 million as it prepares to launch a pivotal phase II trial for its immuno-oncology drug HMBD-002, while managing a CEO transition and tightening cash reserves.

WhiteHawk Limited has secured strong progress on its U.S. Federal cyber resilience contract, received most of the initial A$356,000 payment, and is negotiating a potential A$2.12 million annual subscription. The company is also implementing a significant operating reset to reduce costs by A$1.24 million annually while expanding U.S. public-sector procurement access.

Amcor’s FY2026 results reflect the full impact of its 2025 Berry Global acquisition, with net sales soaring 57% to $23.5 billion and net income more than doubling to $1.1 billion. The company also announced a fiscal year-end change and a raised dividend.

Temas Resources posted a CAD 2.63 million loss for H1 2026, driven by ramped-up exploration and RCL technology development, while securing $1.5 million in fresh funding and signing initial RCL licensing contracts.

BauMart Holdings has secured $244,463 through a placement of over 24 million shares at one cent each, aiming to bolster its BuildMart Modular operations and general working capital.

Anteris Technologies posted a $51.7 million loss in H1 2026 amid ramped-up R&D and clinical trial activity, supported by a $320 million capital raise and Medicare reimbursement for its DurAVR heart valve trial.

EBR Systems marked a commercial milestone with over 100 WiSE CRT implants and secured purchasing agreements with three major US healthcare networks. The company is progressing toward Medicare coverage and scaling manufacturing, supported by a near-complete A$150 million capital raise.

Vection Technologies has locked in $1.2 million in non-repayable government funding to advance four distinct R&D projects spanning AI, Extended Reality, digital health, and inclusive technology.

AVITA Medical posted robust Q2 2026 results with 18% revenue growth, driven by RECELL and supported by Cohealyx and PermeaDerm, and now expects to reach cash flow breakeven by year-end.

Ionic Rare Earths (ASX: IXR) has secured $8 million through a placement to back its Belfast Plant commercialisation and US growth plans, supported by a mix of domestic and international investors including a strategic US partner.